DHMEQ racemate is a NF-κB inhibitor. DHMEQ racemate is less active than (-)-DHMEQ. IC50 & Target: NF-κB^[1] In Vitro: DHMEQ racemate (DHM3EQ) and (-)-DHMEQ (DHM2EQ) inhibits TNF-a-induced NF-kB activation. (-)-DHMEQ is more potent and less toxic than DHMEQ racemate^[1]. In Vivo: The antiarthritic effects of (-)-DHMEQ (DHM2EQ) and DHMEQ racemate (DHM3EQ) are examined on type-II collagen-induced arthritis in DBA1/J mice. This animal model is widely used for evaluation of antirheumatic drugs because of its pathological similarities to human rheumatoid arthritis. The arthritis is elicited and scored. (-)-DHMEQ markedly inhibits type-II-collagen-induced arthritis in mice, whereas DHMEQ racemate tends to only slightly inhibit it^[1].